Cardiovascular Deal Benchmarks
Heart failure, hypertension, ATTR cardiomyopathy, and PAH deal benchmarks. Benchmarks derived from 155 verified transactions.
155
Total Deals
$668M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
58
license
61
acquisition
27
collaboration
3
option
6
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
35Pharma → GSK HS-235 | acquisition | $950M | $950M | Mar 2026 |
35Pharma → GSK HS235 | acquisition | $950M | $950M | Mar 2026 |
35Pharma → GSK pulmonary hypertension drug | acquisition | $950M | $950M | Mar 2026 |
35Pharma → GSK HS235 | acquisition | $950M | $950M | Mar 2026 |
35Pharma → GSK HS-235 | acquisition | $950M | $950M | Mar 2026 |
Tenaya Therapeutics Inc. → Alnylam Pharmaceuticals Inc. | collaboration | $10M | $1.1B | Mar 2026 |
Tenaya Therapeutics → Alnylam Pharmaceuticals | collaboration | $10M | $1.1B | Mar 2026 |
Tenaya Therapeutics Inc. → Alnylam Pharmaceuticals Inc. | collaboration | $10M | $1.1B | Mar 2026 |
35Pharma Inc. → GSK plc HS-235 | acquisition | $950M | $950M | Mar 2026 |
35Pharma → GSK HS235 | acquisition | $950M | $950M | Mar 2026 |
Benchmark Your Cardiovascular Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 155 verified cardiovascular transactions.
Run Cardiovascular Benchmark